Sign in Subscribe
Cancer

Comparative Outcomes of Metastatic Prostate Cancer Patients with DNA Damage Response Gene Alterations

Strategic Insights

— 2 min read

Researchers from the University of Ottawa have investigated the impact of DNA damage response (DDR) gene alterations on the prognosis and treatment outcomes of metastatic prostate cancer (mPC) patients. The study enrolled 169 patients with DDR-a, who were compared to 48 patients without DDR-a (DDR-p). The primary endpoint was overall survival (OS) from diagnosis of mPC, while secondary endpoints included OS and progression-free survival (PFS) from initial diagnosis of prostate cancer, PSA response after 12 weeks, and PFS and OS from the start time of 1st and 2nd line therapies.

Key Takeaways:

  • The study found that DDR-a patients had a similar clinical behaviour compared to DDR-p patients, with no significant differences in overall survival (OS) from diagnosis of mPC (65.7 vs 51.0 mos, p=0.487), OS from initial diagnosis (94.1 vs 88.9 mos, p=0.865), PFS on 1st line therapy (33.2 vs 31.0 mos, p=0.847), and OS on 1st line therapy (85.6 vs 78.6 mos, p=0.799).
  • The most frequent DDR-a were BRCA2 (n=11) and ATM (n=6), with 23 DDR-a and 48 DDR-p patients identified in the study.
  • Baseline characteristics, including age at diagnosis, were similar between the two groups.
  • The study concludes that collaborative efforts are required to better define this molecular cohort of patients.
  • The study adds to the growing literature characterizing the clinical behaviour of DDR-a mPC.

Statistics:

  • 169 patients with DDR-a were enrolled in the study.
  • 48 patients without DDR-a (DDR-p) served as the control group.
  • 23 DDR-a patients were identified.
  • 11 DDR-a patients had BRCA2 mutations.
  • 6 DDR-a patients had ATM mutations.
  • 73.9% of DDR-a patients received androgen deprivation therapy (ADT) as 1st line systemic therapy.
  • 65% of DDR-a patients received abiraterone or enzalutamide as 2nd line therapy.
  • 52% of DDR-a patients received olaparib.
  • 65.7 months was the mean OS from mPC diagnosis for DDR-a patients.
  • 94.1 months was the mean OS from initial diagnosis of prostate cancer for DDR-a patients.
  • 33.2 months was the mean PFS on 1st line therapy for DDR-a patients.
  • 85.6 months was the mean OS on 1st line therapy for DDR-a patients.

Sources:

  • Comparative outcomes of metastatic prostate cancer (mPC) patients (pts) with DNA damage response gene alterations (DDR-a): A single-center experience. Journal of Clinical Oncology, 2023,41(6_suppl).
  • University of Ottawa, Ottawa, ON, Canada.
  • American Society of Clinical Oncology (ASCO).

Read more